| [1] |
Saha SK, Zhu AX, Fuchs CS, et al. Forty-year trends in cholangiocarcinoma incidence in the US: intrahepatic disease on the rise[J]. Oncologist, 2016, 21(5):594-599.
|
| [2] |
Wirth TC, Vogel A. Surveillance in cholangiocellular carcinoma[J]. Best Pract Res Clin Gastroenterol, 2016, 30(6):987-999.
|
| [3] |
Bridgewater J, Galle PR, Khan SA, et al. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma[J]. J Hepatol, 2014, 60(6):1268-1289.
|
| [4] |
Yoh T, Hatano E, Yamanaka K, et al. Is surgical resection justified for advanced intrahepatic cholangiocarcinoma?[J]. Liver Cancer, 2016, 5(4):280-289.
|
| [5] |
Moss AC, Morris E, Leyden J, et al. Malignant distal biliary obstruction: a systematic review and meta-analysis of endoscopic and surgical bypass results[J]. Cancer Treat Rev, 2007, 33(2):213-221.
|
| [6] |
O'Brien S, Bhutiani N, Egger ME, et al. Comparing the efficacy of initial percutaneous transhepatic biliary drainage and endoscopic retrograde cholangiopancreatography with stenting for relief of biliary obstruction in unresectable cholangiocarcinoma[J]. Surg Endosc, 2020, 34(3):1186-1190.
|
| [7] |
Moole H, Dharmapuri S, Duvvuri A, et al. Endoscopic versus percutaneous biliary drainage in palliation of advanced malignant hilar obstruction: a meta-analysis and systematic review[J]. Can J Gastroenterol Hepatol, 2016:4726078.
|
| [8] |
Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer[J]. N Engl J Med, 2010, 362(14): 1273-1281.
|
| [9] |
Konstantinidis IT, Groot Koerkamp B, Do RKG, et al. Unresectable intrahepatic cholangiocarcinoma: systemic plus hepatic arterial infusion chemotherapy is associated with longer survival in comparison with systemic chemotherapy alone[J]. Cancer, 2016, 122(5):758-765.
|
| [10] |
Jackson MW, Amini A, Jones BL, et al. Treatment selection and survival outcomes with and without radiation for unresectable, localized intrahepatic cholangiocarcinoma[J]. Cancer J, 2016, 22(4): 237-242.
|
| [11] |
Song JH, Kang KM, Choi HS, et al. Comparing the clinical outcomes in stereotactic body radiotherapy for lung tumors between Ray-Tracing and Monte-Carlo algorithms[J]. Oncotarget, 2016, 7(14):19045-19053.
|
| [12] |
Mahadevan A, Dagoglu N, Mancias J, et al. Stereotactic body radiotherapy (SBRT) for intrahepatic and hilar cholangiocarcinoma[J]. J Cancer, 2015, 6(11):1099-1104.
|
| [13] |
Shen ZT, Zhou H, Li AM, et al. Clinical outcomes and prognostic factors of stereotactic body radiation therapy for intrahepatic cholangiocarcinoma[J]. Oncotarget, 2017, 8(55):93541-93550.
|
| [14] |
Ohkawa A, Mizumoto M, Ishikawa H, et al. Proton beam therapy for unresectable intrahepatic cholangiocarcinoma[J]. J Gastroenterol Hepatol, 2015, 30(5):957-963.
|
| [15] |
Cucchetti A, Cappelli A, Mosconi C, et al. Improving patient selection for selective internal radiation therapy of intra-hepatic cholangiocarcinoma:a meta-regression study[J]. Liver Int, 2017, 37(7): 1056-1064.
|
| [16] |
Edeline J, Touchefeu Y, Guiu B, et al. Radioembolization plus chemotherapy for first-line treatment of locally advanced intrahepatic cholangiocarcinoma: a phase 2 clinical trial[J]. JAMA Oncol, 2019, 6(1):51-59.
|
| [17] |
Malka D, Cervera P, Foulon S, et al. Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial[J]. Lancet Oncol, 2014, 15(8):819-828.
|
| [18] |
Chen JS, Hsu C, Chiang NJ, et al. A KRAS mutation status-stratified randomized phase Ⅱ trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancer[J]. Ann Oncol, 2015, 26(5):943-949.
|
| [19] |
Cai W, Yuan Y, Ge W, et al. EGFR target therapy combined with gemox for advanced biliary tract cancers:a meta-analysis based on RCTs[J]. J Cancer, 2018, 9(8):1476-1485.
|
| [20] |
Valle JW, Wasan H, Lopes A, et al. Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial[J]. Lancet Oncol, 2015, 16(8):967-978.
|
| [21] |
Bahleda R, Italiano A, Hierro C, et al. Multicenter phase I study of erdafitinib (JNJ-42756493), oral pan-fibroblast growth factor receptor inhibitor, in patients with advanced or refractory solid tumors[J]. Clin Cancer Res, 2019, 25(16):4888-4897.
|
| [22] |
Javle M, Lowery M, Shroff RT, et al. Phase II study of BGJ398 in patients with FGFR-altered advanced cholangiocarcinoma[J]. J Clin Oncol, 2018, 36(3):276-282.
|
| [23] |
Lowery MA, Burris HA 3rd, Janku F, et al. Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study[J]. Lancet Gastroenterol Hepatol, 2019, 4(9): 711-720.
|
| [24] |
Ioka T, Ueno M, Oh D, et al. Evaluation of safety and tolerability of durvalumab (D) with or without tremelimumab (T) in patients (pts) with biliary tract cancer (BTC)[J]. J Clin Oncol, 2019, 37(7):387.
|
| [25] |
Sui M, Li Y, Wang H, et al. Two cases of intrahepatic cholangiocellular carcinoma with high insertion-deletion ratios that achieved a complete response following chemotherapy combined with PD-1 blockade[J].J Immunother Cancer, 2019, 7(1):125.
|
| [26] |
Mou H, Yu L, Liao Q, et al. Successful response to the combination of immunotherapy and chemotherapy in cholangiocarcinoma with high tumour mutational burden and PD-L1 expression: a case report[J]. BMC cancer, 2018, 18(1):1105.
|
| [27] |
Yousaf A, Kim JU, Eliahoo J, et al. Ablative therapy for unresectable intrahepatic cholangiocarcinoma: a systematic review and meta-analysis[J]. J Clin Exp Hepatol, 2019, 9(6):740-748.
|
| [28] |
Zhang K, Yu J, Yu X, et al. Clinical and survival outcomes of percutaneous microwave ablation for intrahepatic cholangiocarcinoma[J]. Int J Hyperthermia, 2018, 34(3):292-297.
|
| [29] |
Sha M, Jeong S, Xia Q. Antiviral therapy improves survival in patients with HBV infection and intrahepatic cholangiocarcinoma undergoing liver resection: novel concerns[J]. J Hepatol, 2018, 68(6):1315-1316.
|
| [30] |
Lei Z, Xia Y, Si A, et al. Antiviral therapy improves survival in patients with HBV infection and intrahepatic cholangiocarcinoma undergoing liver resection[J]. J Hepatol, 2018, 68(4):655-662.
|
| [31] |
Li J, Lei Z, Wang K, et al. Reply to: "Antiviral therapy improves survival in patients with HBV infection and intrahepatic cholangiocarcinoma undergoing liver resection: novel concerns"[J].J Hepatol, 2018, 68(6):1316-1318.
|